Companies agree $800m deal for off-the-shelf in vivo CAR-T cell therapy
Drug Discovery World
FEBRUARY 22, 2024
Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Xyphos will be responsible for the development and commercialisation of products created from the collaborative research.
Let's personalize your content